M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

NCT03631706 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

304

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: M7824
DRUG: Pembrolizumab

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

[object Object]